Literature DB >> 29521028

Beta-blockers, hypertension, and stroke outcomes.

Magnus O Wijkman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29521028      PMCID： PMC8030948          DOI： 10.1111/jch.13234

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  12 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

Review 3.  Stroke.

Authors:  Graeme J Hankey
Journal:  Lancet       Date:  2016-09-13       Impact factor: 79.321

4.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Authors:  George L Bakris; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; Robert A Phillips; Philip Raskin; Jackson T Wright; Rosemary Oakes; Mary Ann Lukas; Karen M Anderson; David S H Bell
Journal:  JAMA       Date:  2004-11-10       Impact factor: 56.272

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

7.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04

8.  Different drug classes have variable effects on blood pressure depending on the time of day.

Authors:  Trefor O Morgan; Adrianne Anderson
Journal:  Am J Hypertens       Date:  2003-01       Impact factor: 2.689

9.  Beta-blockers, hypertension, and stroke outcomes.

Authors:  Magnus O Wijkman
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-09       Impact factor: 3.738

10.  A comparison of atenolol and nebivolol in isolated systolic hypertension.

Authors:  Zahid Dhakam; Carmel M McEniery; Tim Burton; Morris J Brown; Ian B Wilkinson
Journal:  J Hypertens       Date:  2008-02       Impact factor: 4.844
View more
  2 in total

1.  Beta-blockers, hypertension, and stroke outcomes.

Authors:  Magnus O Wijkman
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-09       Impact factor: 3.738

2.  Effectiveness and safety of Xuefu Zhuyu decoction for treating coronary heart disease angina: A systematic review and meta-analysis.

Authors:  Tao Yang; Xiao Li; Ziwen Lu; Xiaowan Han; Mingjing Zhao
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.